Nexium IV

/ Astra Zeneca

Adults: Gastric antisecretory treatment when the oral route is not possible.
Patients who cannot take oral medication may be treated parenterally with 20-40 mg once daily. Patients with reflux esophagitis should be treated with 40 mg once daily. Patients treated symptomatically for reflux disease should be treated with 20 mg once daily.
Usually the IV treatment duration is short and transfer to oral treatment should be made as soon as possible.
Prevention of rebleeding of gastric and duodenal ulcers.
Following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be administered as a bolus infusion over 30 minutes, followed by a continuous intravenous infusion of 8 mg/h given over 3 days (72 hours).
The parenteral treatment period should be followed by oral acid-suppression therapy.
See prescribing information for full details.

Indicated in adult for:
• Gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate.
• Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Indicated in children and adolescents aged 1-18 years for:
• Gastric antisecretory treatment when the oral route is not possible, such as:
gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.

Hypersensitivity to the active substance esomeprazole or to other substituted
benzimidazoles or to any of the excipients of this medicinal product.
Esomeprazole should not be used concomitantly with nelfinavir

In the presence of any alarm symptom (e.g., significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis. Impaired renal function: Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution. Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum daily dose of 20 mg should not be exceeded. Should not be used in children since no data is available.
See prescribing information for full details.

Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose-related adverse reactions have been identified.
See prescribing information for full details.

Drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc. Warfarin or other coumarin derivatives.
See prescribing information for full details.

Pregnancy: Caution should be exercised when treating pregnant women.
Lactation: Should not be used during breast-feeding.